Array Biopharma Inc (NASDAQ:ARRY) advanced 2.82% to end last trading session at $5.84. The company, on August 3, 2015, reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.
On the trading floor, shares of Array Biopharma Inc (NASDAQ:ARRY) gained 3.82% to close at $5.43. The $722.93M company on July 22, 2015 announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of ...
Array BioPharma Inc. (NASDAQ:ARRY) has witnessed a drop of 0.9% or 227,716 shares in its short figure. The short interest diminution took it from 26,235,056 on July 15,2015 to 26,007,340 on July 31,2015.
Array BioPharma Inc. (NASDAQ:ARRY) has lost 10.55% during the past week and dropped 16.69% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 8.53%.